Evidence map›Paper›PMID 26459896›Full record

ArticleAntimicrobial agents and chemotherapy2016

The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.

Venée N Tubman, Pedro Mejia, Boris E Shmukler, Amy K Bei, Seth L Alper, James R Mitchell, Carlo Brugnara, Manoj T Duraisingh

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Entry inhibitors as arenavirus antivirals.Frontiers in microbiology · 2024
    Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Venée N TubmanDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Pedro MejiaDepartment of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Boris E ShmuklerRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Amy K BeiDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Seth L AlperRenal Division and Vascular Biology Research Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
James R MitchellDepartment of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts, USA.
Carlo BrugnaraDepartment of Laboratory Medicine, Boston Children's Hospital, Boston, Massachusetts, USA carlo.brugnara@childrens.harvard.edu mduraisi@hsph.harvard.edu.
Manoj T DuraisinghDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA carlo.brugnara@childrens.harvard.edu mduraisi@hsph.harvard.edu.
Harvard University · USBeth Israel Deaconess Medical Center · USBoston Children's Hospital · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
PATHOPHYSIOLOGY OF HUMAN BLOOD CELLST32HL007574 · NHLBI · CHILDREN'S HOSPITAL BOSTON · PI Daniel Evan Bauer · 1985 to 2026
$18.4M
Functional analysis of erythrocyte determinants of malaria infectionR01AI091787 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DURAISINGH, MANOJ T · 2011 to 2015
$2.0M
Intramural NIH HHSNCRR NIH HHS UL1 RR025758NHLBI NIH HHS T32 HL007574NIAID NIH HHS R01 AI091787
6 · The paper itself

Abstract

Senicapoc, a Gardos channel inhibitor, prevented erythrocyte dehydration in clinical trials of patients with sickle cell disease. We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits Plasmodium growth. Senicapoc inhibited in vitro growth of human and primate plasmodia during the clinical blood stage. Senicapoc treatment suppressed P. yoelii parasitemia in vivo in C57BL/6 mice. The reassuring safety and biochemical profile of senicapoc encourage its use in antimalarial development.

Indexed as

AcetamidesAnimalsAntimalarialsBiological TransportErythrocytesHost-Parasite InteractionsHumansIntermediate-Conductance Calcium-Activated Potassium ChannelsMacaca mulattaMiceMice, Inbred C57BLPlasmodium falciparumPlasmodium knowlesiPlasmodium yoeliiTriphenylmethyl CompoundsTrophozoitesAcetamidesAntimalarialsIntermediate-Conductance Calcium-Activated Potassium ChannelsKCNN4 protein, humanKcnn4 protein, mousesenicapocTriphenylmethyl CompoundsWater

Identifiers

PMID26459896
PMCPMC4704178
OpenAlexW2217604408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.